Hashimoto Thyroiditis

Detailed Overview

Hashimoto Thyroiditis represents a classic organ-specific autoimmune disease. It often presents insidiously, with patients remaining euthyroid for years before progressing to subclinical, and eventually overt, hypothyroidism. Goiter is a common physical finding due to lymphocytic infiltration and TSH-mediated compensatory hypertrophy. Diagnosis relies on the presence of circulating anti-thyroid peroxidase (anti-TPO) antibodies. The clinical significance lies in its widespread systemic effects when hypothyroidism develops, impacting metabolism, cardiovascular health, and neurocognition.

Epidemiology & Demographics

The most common cause of hypothyroidism in the US. Prevalence is approximately 5% in Caucasian populations. Striking female predominance with a female-to-male ratio of 7-10:1. Peak incidence occurs between 30 and 50 years of age.

Etiological Mechanism

A complex interplay of genetic susceptibility (HLA-DR3, HLA-DR5, CTLA-4, PTPN22 polymorphisms) and environmental triggers. The immune system loses tolerance to thyroid autoantigens, primarily Thyroid Peroxidase (TPO) and Thyroglobulin (Tg).

Primary Causes

Autoimmune destruction mediated by T-cells and B-cells. Environmental triggers may include high iodine intake, viral infections, stress, and radiation exposure. Associated with other autoimmune conditions (Type 1 Diabetes, Celiac disease).

• Female Sex and Age: Women aged 30-50 are at the highest risk, largely due to the influence of sex hormones on immune tolerance.
• Family History: Strong familial clustering of autoimmune thyroid disease or other autoimmune disorders.

The pathogenesis involves CD4+ T-cell activation against thyroid antigens, recruiting CD8+ cytotoxic T-cells and B-cells. CD8+ T-cells directly destroy thyroid follicular cells via perforin/granzyme and Fas-mediated apoptosis. B-cells differentiate into plasma cells, producing autoantibodies (anti-TPO and anti-Tg). Anti-TPO antibodies fix complement and cause antibody-dependent cell-mediated cytotoxicity (ADCC). The persistent immune attack leads to the replacement of normal thyroid parenchyma with dense lymphocytic infiltrates, lymphoid germinal centers, and fibrosis (Hürthle cell metaplasia). As functional follicles are destroyed, T3/T4 levels drop, removing negative feedback on the pituitary, resulting in elevated TSH levels.

Characteristic Clinical Presentation

• Fatigue and Lethargy: Profound lack of energy and increased sleep requirement due to a generalized slowing of metabolic rate.
• Cold Intolerance: Feeling constantly cold due to decreased basal metabolic rate and reduced thermogenesis.
• Weight Gain: Unexplained mild weight gain (typically 5-10 lbs) despite poor appetite, primarily due to decreased metabolic rate and myxedema (fluid retention).

Physical Examination Signs

• Goiter: Firm, non-tender, rubbery, diffusely enlarged thyroid gland.
• Delayed relaxation phase of deep tendon reflexes (Woltman sign).
• Bradycardia, dry/coarse skin, and loss of the outer third of the eyebrows (Queen Anne's sign).

• Myxedema Coma: A rare, life-threatening decompensation of severe hypothyroidism presenting with hypothermia, bradycardia, altered mental status, and respiratory depression.
• Primary Thyroid Lymphoma: Patients have an 80-fold increased risk of developing B-cell non-Hodgkin lymphoma of the thyroid, typically presenting as rapidly enlarging goiter.

Diagnostic Criteria & Guidelines

Diagnosis is established by the presence of primary hypothyroidism (Elevated TSH, Low Free T4) in combination with positive anti-TPO or anti-Tg antibodies. In euthyroid patients with a goiter, positive antibodies alone suggest Hashimoto's.

Differential Diagnosis

• Iodine Deficiency Goiter
• Subacute (De Quervain's) Thyroiditis
• Riedel Thyroiditis

Laboratory Tests & Biomarkers

• Serum TSH: Elevated (> 4.5 mIU/L; often > 10 mIU/L in overt disease).
• Free T4: Decreased (typically < 0.8 ng/dL in overt disease).
• Anti-TPO Antibodies: Elevated in >90% of patients (e.g., > 35 IU/mL).

Imaging Modalities & Findings

• Thyroid Ultrasound:

• Euthyroid Phase
  Normal TSH and T4; positive antibodies. Often incidentally found goiter.
• Subclinical Hypothyroidism
  Elevated TSH (>4.5 mIU/L) with normal Free T4. Symptoms may be mild or absent.
• Overt Hypothyroidism
  Elevated TSH and low Free T4. Classic hypothyroid symptoms present.

Second-Line & Adjunctive Therapy

No universally accepted second-line for Hashimoto's. Desiccated thyroid extract (e.g., Armour Thyroid) or Liothyronine (synthetic T3) are generally not recommended by guidelines due to unphysiologic T3/T4 ratios but are occasionally used in patients whose symptoms persist despite normal TSH on levothyroxine.

Surgical & Procedural Management

Thyroidectomy is rarely indicated. May be performed for a massive goiter causing compressive symptoms (dysphagia, tracheal deviation) or if primary thyroid lymphoma or coexisting malignancy is suspected.

Recommended Lifestyle Changes

• Ensure adequate, but not excessive, dietary iodine intake. Avoid large iodine supplements (like kelp) as they can worsen autoimmune attack via the Wolff-Chaikoff effect.
• Consider screening for Celiac disease if GI symptoms are present, due to frequent co-occurrence.

Patient Counseling & Advice

Levothyroxine must be taken daily, exactly as prescribed, without food or other medications (especially iron, calcium, or PPIs) that interfere with absorption. It is a lifelong replacement therapy.

Follow-Up & Monitoring Schedule

Check TSH every 6-8 weeks after initiating or changing the Levothyroxine dose until euthyroid (target TSH 0.5 - 4.5 mIU/L). Once stable, check TSH annually.

Preventive Strategies

No known preventive measures. Screening TSH is recommended for pregnant women or those with other autoimmune diseases.

Excellent. With appropriate Levothyroxine replacement, patients have a normal life expectancy and complete symptom resolution. The gland often eventually shrinks and becomes atrophic.